Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa study of fourth-generation GPC3 CAR-T cells in advanced hepatocellular carcinoma
ChiCTR2000036458Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Aug 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of AZD7003 in hepatocellular carcinoma (HCC) (3 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Safety and tolerability. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
AZD7003
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000036458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036458.